Unleashing the full potential of myeloid cells
PrimeBody is an antibody-based therapeutics platform utilizing an all-in-one approach of tumor-activation and targeting for cancer immunotherapy
Multi-specific modular platform for single agent activity, high tumor specificity, systemic administration, and wide therapeutic index
Myeloid immune checkpoint inhibitor
Myeloid immune stimulator
In healthy peripheral tissue
In tumor microenvironment
myeloid immune checkpoint inhibitor remains inactive in healthy issue
myeloid immune checkpoint inhibitor is selectively activated in TME
This is a conceptual schematic for illustrative purposes
PrimeBody orchestrates innate and adaptive immune response in a tumor-selective manner for long-term cancer immunity
Voro Therapeutics is primed to transform cancer immunotherapy
Voro's proprietary masking technology combined with modular elements are primed to initiate an immune response with myeloid cells that can than recruit and educate T and NK cells.
Avoid on-target systemic toxicity
Conventional biologics exhibit on-target systemic toxicity and broad tissue distribution, leading to poor therapeutic index.
PrimeBodies stay masked until they reach their target tumor tissue, avoiding systemic toxicity and allowing a higher therapeutic index to be achieved.